The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | AlloSCT outcomes in patients who achieve CR with CAR-T versus chemotherapy in T-ALL/LBL
Peihua Lu, MD, Beijing Lu Daopei Institute of Hematology, and Hebei Yanda Lu Daopei Hospital, Langfang, China, discusses a comparison of CAR-T therapy versus chemotherapy prior to allogeneic stem cell transplantation (alloSCT) in T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma (T-ALL/LBL). In patients who achieved complete remission (CR) before alloSCT, there was no difference in disease-free survival (DFS) and overall survival (OS) between the two treatment regimens. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
